Durata Therapeutics Company Profile (NASDAQ:DRTX)

Analyst Ratings

Consensus Ratings for Durata Therapeutics (NASDAQ:DRTX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Durata Therapeutics (NASDAQ:DRTX)
Show:
DateFirmActionRatingPrice TargetActions
10/15/2014Roth CapitalDowngradeBuy -> Neutral$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/14/2014Credit Suisse Group AGDowngradeOutperform -> Neutral$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/7/2014Royal Bank Of CanadaDowngradeOutperform -> Sector PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/6/2014JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Jefferies GroupLower Price Target$15.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Durata Therapeutics (NASDAQ:DRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/7/2014Q2($0.73)($0.61)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.64)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2014Q413($0.76)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013($0.60)($0.45)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.52)($0.75)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/20131Q13($0.66)($0.86)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($1.00)($1.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Durata Therapeutics (NASDAQ:DRTX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Durata Therapeutics (NASDAQ:DRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/12/2014John Patrick Shannon JrInsiderBuy3,000$13.72$41,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2014Paul R EdickCEOBuy3,000$15.23$45,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Schutter Richard DeDirectorBuy15,000$15.57$233,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Aisling Capital Iii Lpmajor shareholderSell100,649$15.74$1,584,215.26View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013Lisa GilesDirectorBuy1,000$10.95$10,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2013Paul R EdickCEOBuy3,000$7.09$21,270.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2012Paul R EdickCEOBuy5,000$8.65$43,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Durata Therapeutics (NASDAQ:DRTX)
DateHeadline
01/20/15 02:30 AMActavis Launches U.S. Generic Specialty Injectable Portfolio - [at noodls] - - Products to be Marketed to Clinics and Hospitals across the United States - - Industry-Leading Pipeline in Development - DUBLIN, Jan. 13, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global ...
10/06/14 07:34 AMActavis buying Durata Therapeutics for $616.4 -

Social

About Durata Therapeutics

Durata Therapeutics logoDurata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: DRTX
  • CUSIP: 26658A10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $0
  • 200 Day Moving Average: $24
  • P/E Ratio: N/A
  • P/E Growth: 0
  • Market Cap: $N/A
  • Current Year EPS Consensus Estimate: $-2.97 EPS
  • Next Year EPS Consensus Estimate: $-1.37 EPS
Additional Links:
Durata Therapeutics (NASDAQ:DRTX) Chart for Sunday, July, 24, 2016